A WHIM satisfactorily addressed
- PMID: 24723677
- DOI: 10.1182/blood-2014-02-557579
A WHIM satisfactorily addressed
Abstract
In this issue of Blood, McDermott et al present the intriguing, clinically relevant, and perhaps unexpected findings for the efficacy and safety of long-term administration of low-dose plerixafor treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome.
Trial registration: ClinicalTrials.gov NCT00967785.
Comment on
-
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.Blood. 2014 Apr 10;123(15):2308-16. doi: 10.1182/blood-2013-09-527226. Epub 2014 Feb 12. Blood. 2014. PMID: 24523241 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

